Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH2853 in relapsed/refractory peripheral T-cell lymphoma
NCT06909877Phase 2Recruiting
- Sponsor
- Haihe
- Start
- Jul 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HH2853 in peripheral T-cell lymphoma (PTCL), sponsored by Haihe. Started Jul 2022; status: recruiting.
02
Drugs
HH2853
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06909877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06909877.